179 related articles for article (PubMed ID: 32117933)
1. Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model.
Sun T; Guo X; Zhong R; Wang C; Liu H; Li H; Ma L; Guan J; You C; Tian M
Front Bioeng Biotechnol; 2020; 8():53. PubMed ID: 32117933
[TBL] [Abstract][Full Text] [Related]
2. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
[TBL] [Abstract][Full Text] [Related]
3. Effects of Chitosan Oligosaccharides on Human Blood Components.
Guo X; Sun T; Zhong R; Ma L; You C; Tian M; Li H; Wang C
Front Pharmacol; 2018; 9():1412. PubMed ID: 30559672
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of oxidation-responsive alginate-deferoxamine conjugates with increased stability and low toxicity.
Tian M; Chen X; Gu Z; Li H; Ma L; Qi X; Tan H; You C
Carbohydr Polym; 2016 Jun; 144():522-30. PubMed ID: 27083844
[TBL] [Abstract][Full Text] [Related]
5. Interactions of oligochitosan with blood components.
Sun T; Guo X; Zhong R; Ma L; Li H; Gu Z; Guan J; Tan H; You C; Tian M
Int J Biol Macromol; 2019 Mar; 124():304-313. PubMed ID: 30445093
[TBL] [Abstract][Full Text] [Related]
6. Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density.
Hamilton JL; Ul-Haq MI; Creagh AL; Haynes CA; Kizhakkedathu JN
Macromol Biosci; 2017 Mar; 17(3):. PubMed ID: 27683190
[TBL] [Abstract][Full Text] [Related]
7. Fluorene methoxycarbonyl-PEG-deferoxamine conjugates "hitchhike" with albumin in situ for iron overload therapy.
Xu L; Guan R; Yu B; Li Y; Liu H; Jiang Y
Int J Pharm; 2022 Sep; 625():122136. PubMed ID: 36029994
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Farr AC; Xiong MP
Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
[TBL] [Abstract][Full Text] [Related]
11. Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo.
Imran ul-haq M; Hamilton JL; Lai BF; Shenoi RA; Horte S; Constantinescu I; Leitch HA; Kizhakkedathu JN
ACS Nano; 2013 Dec; 7(12):10704-16. PubMed ID: 24256569
[TBL] [Abstract][Full Text] [Related]
12. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
Liu Z; Lin TM; Purro M; Xiong MP
ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
[TBL] [Abstract][Full Text] [Related]
13. First human studies with a high-molecular-weight iron chelator.
Dragsten PR; Hallaway PE; Hanson GJ; Berger AE; Bernard B; Hedlund BE
J Lab Clin Med; 2000 Jan; 135(1):57-65. PubMed ID: 10638695
[TBL] [Abstract][Full Text] [Related]
14. Effects of extracts and isolated compounds from safflower on some index of promoting blood circulation and regulating menstruation.
Yao D; Wang Z; Miao L; Wang L
J Ethnopharmacol; 2016 Sep; 191():264-272. PubMed ID: 27286914
[TBL] [Abstract][Full Text] [Related]
15. Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile.
Nasrallah GK; Salem R; Da'as S; Al-Jamal OLA; Scott M; Mustafa I
Neurotoxicol Teratol; 2019; 72():29-38. PubMed ID: 30710618
[TBL] [Abstract][Full Text] [Related]
16. Decorporation of Iron Metal Using Dialdehyde Cellulose-Deferoxamine Microcarrier.
Tyagi P; Kumar A; Gupta D; Singh H
AAPS PharmSciTech; 2017 Jan; 18(1):156-165. PubMed ID: 26912356
[TBL] [Abstract][Full Text] [Related]
17. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
Hallaway PE; Eaton JW; Panter SS; Hedlund BE
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311
[TBL] [Abstract][Full Text] [Related]
18. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
19. A Novel Star Like Eight-Arm Polyethylene Glycol-Deferoxamine Conjugate for Iron Overload Therapy.
Yu B; Yang Y; Liu Q; Zhan A; Yang Y; Liu H
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32272723
[TBL] [Abstract][Full Text] [Related]
20. Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Komoto K; Nomoto T; El Muttaqien S; Takemoto H; Matsui M; Miura Y; Nishiyama N
Cancer Sci; 2021 Jan; 112(1):410-421. PubMed ID: 32770631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
